A second novel drug target has been generated in AstraZeneca and BenevolentAI’s artificial intelligence-assisted drug discovery partnership, this time in idiopathic pulmonary fibrosis (IPF).
AstraZeneca And BenevolentAI Advance AI Partnership With Second Novel Target
Focus On Biology Paying Off
AstraZeneca and BenevolentAI claim their partnership is augmenting and accelerating validation of new drug targets.
More from Respiratory
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.